EMA places Zhejiang Huahai under ‘increased supervision’ over quality issues

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/ChakisAtelier)
(Image: Getty/ChakisAtelier)

Related tags valsartan Ema Zhejiang Huahai

The EMA has placed Zhejiang Huahai under supervision, after the firm produced valsartan medication contaminated by probable carcinogens.

The decision will see the European Medicines Agency (EMA) supervise the Chinese company’s manufacturing process to monitor the implementation of corrective measures.

According to the agency, this would see it monitor the company “on a regular basis and increase the frequency of inspections of the site. In addition, marketing authorisation holders for EU medicines will be required to perform additional tests on all active substances supplied by Zhejiang Huahai.”

The action arrives as part of an investigation into Zhejiang Huahai, after impurities in the valsartan active ingredient produced by the company sparked a global recall of medicines​.

Initially, the product was thought to be contaminated with only N-nitrosodimethylamine (NDMA), but this later extended to include N-nitrosodiethylamine (NDEA) – both are listed by the WHO​ as probable carcinogens.

The EMA will take action to monitor all active substances manufactured by Zhejiang Huahai, though it noted contaminants had not been found in any of the company’s other products.

Not one company, nor one product

The scope of the overall investigation has widened rapidly since July of this year, to include more than one compan​y and more than one ingredient​.

A further company has been drawn into the investigation, due to the agency discovering NDEA contamination within Aurobindo Pharma’s production of irbesartan. As a result, the agency released a notice that irbesartan produced by the company would no longer be allowed into the EU.

It also outlined that the investigation will continue into other ‘sartans’, specifically candesartan, irbesartan, losartan, and olmesartan.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more